Watch List: Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Mylan Inc (NASDAQ:MYL), The Cooper Companies, (NYSE:COO), Dr. Reddy’s Laboratories Limited (NYSE:RDY), Endo International (NASDAQ:ENDP)

On June 25, 2014, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced the filing of a preliminary proxy statement for a special meeting of shareholders, at which Valeant shareholders will consider and vote upon, among other things, a proposal to approve the issuance of Valeant common shares in connection with an acquisition of Allergan, Inc. (“Allergan”) (NYSE: AGN). Valeant commenced an exchange offer for the common stock of Allergan on June 18, 2014. Valeant Pharmaceuticals Intl Inc (NYSE:VRX), net profit margin is -13.10% and weekly performance is 5.68%. On last trading day company shares ended up $128.85. Analysts mean target price for the company is $52.38. Valeant Pharmaceuticals Intl Inc (NYSE:VRX), distance from 50-day simple moving average (SMA50) is 0.48%.

On June 11, 2014, Mylan Inc (NASDAQ:MYL), announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott’s Actonel Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Mylan Inc (NASDAQ:MYL), fell 0.69% in last trading session and ended the day on $51.51. MYL, Gross Margin is 44.80% and its return on assets is 4.50%. Mylan Inc (NASDAQ:MYL), quarterly performance is 6.03%.

The Cooper Companies, Inc. (NYSE:COO), has been given an average rating of “Hold” by the nine analysts that are covering the stock,Analyst Ratings Net reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $137.83. The Cooper Companies, Inc. (NYSE:COO), shares moved up 1.02% in last trading session and was closed at $137.04, while trading in range of $134.42 – 137.12. The Cooper Companies, Inc. (NYSE:COO), year to date (YTD) performance is 10.69%.

On June 27, 2014, Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY), announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2014 was filed with the United States Securities and Exchange Commission on June 26, 2014. Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY), ended the last trading day at $42.57. Company weekly volatility is calculated as 1.22% and price to cash ratio as 13.93. Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY), showed a positive weekly performance of 5.24%.

On June 25, 2014, Endo International PLC (NASDAQ:ENDP), announced that Endo Finance LLC and Endo Finco Inc., its wholly-owned subsidiaries, priced $750 million aggregate principal amount of 5.375% senior notes due January 2023 at an issue price of $1,000 per $1,000 principal amount in connection with their previously announced private offering. The notes will be unsecured, unsubordinated obligations of Endo Finance LLC and Endo Finco Inc. and will be guaranteed by Endo Limited, a wholly-owned subsidiary of Endo, and certain of Endo Limited’s direct and indirect subsidiaries. Endo International PLC (NASDAQ:ENDP), net profit margin is -41.00% and weekly performance is 3.46%. On last trading day company shares ended up $70.34. Analysts mean target price for the company is $73.05. Endo International PLC (NASDAQ:ENDP), distance from 50-day simple moving average (SMA50) is 3.69%.